Cocrystal Pharma, Inc.

NasdaqCM:COCP Stock Report

Market Cap: US$15.3m

Cocrystal Pharma Past Earnings Performance

Past criteria checks 0/6

Cocrystal Pharma has been growing earnings at an average annual rate of 10.2%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 53.3% per year.

Key information

10.2%

Earnings growth rate

38.5%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-53.3%
Return on equity-58.7%
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14
Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19
We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19
Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06
We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05
We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13
Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Jan 24
What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Cocrystal sees 2021 cash burn of $800k a month

Jan 11

Cocrystal Pharma to test CDI-45205 against coronaviruses

Dec 22

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Dec 20
Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Revenue & Expenses Breakdown
Beta

How Cocrystal Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:COCP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-1860
30 Jun 230-2060
31 Mar 230-4060
31 Dec 220-3960
30 Sep 220-3850
30 Jun 220-3660
31 Mar 220-1660
31 Dec 210-1450
30 Sep 211-1260
30 Jun 211-1150
31 Mar 212-1060
31 Dec 202-1060
30 Sep 202-5660
30 Jun 202-5560
31 Mar 202-5350
31 Dec 197-4850
30 Sep 196-4550
30 Jun 196-4550
31 Mar 195-4540
31 Dec 180-4940
30 Sep 180040
30 Jun 180040
31 Mar 180030
31 Dec 170-130
30 Sep 170-7230
30 Jun 170-7120
31 Mar 170-7330
31 Dec 160-7540
30 Sep 160-4060
30 Jun 160-3880
31 Mar 160-3880
31 Dec 150-5070
30 Sep 150-2240
30 Jun 150-2430
31 Mar 150-1620
31 Dec 140020
30 Sep 14011-3
30 Jun 14031-2
31 Mar 140-31-1

Quality Earnings: COCP is currently unprofitable.

Growing Profit Margin: COCP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: COCP is unprofitable, but has reduced losses over the past 5 years at a rate of 10.2% per year.

Accelerating Growth: Unable to compare COCP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: COCP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).


Return on Equity

High ROE: COCP has a negative Return on Equity (-58.72%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.